Precigen (PGEN) Competitors $1.52 -0.31 (-16.94%) Closing price 07/22/2025 04:00 PM EasternExtended Trading$1.56 +0.04 (+2.96%) As of 07/22/2025 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock PGEN vs. CNTA, BEAM, TWST, KNSA, IRON, GLPG, CGON, ARWR, HRMY, and DNLIShould you be buying Precigen stock or one of its competitors? The main competitors of Precigen include Centessa Pharmaceuticals (CNTA), Beam Therapeutics (BEAM), Twist Bioscience (TWST), Kiniksa Pharmaceuticals International (KNSA), Disc Medicine (IRON), Galapagos (GLPG), CG Oncology (CGON), Arrowhead Pharmaceuticals (ARWR), Harmony Biosciences (HRMY), and Denali Therapeutics (DNLI). These companies are all part of the "pharmaceutical products" industry. Precigen vs. Its Competitors Centessa Pharmaceuticals Beam Therapeutics Twist Bioscience Kiniksa Pharmaceuticals International Disc Medicine Galapagos CG Oncology Arrowhead Pharmaceuticals Harmony Biosciences Denali Therapeutics Centessa Pharmaceuticals (NASDAQ:CNTA) and Precigen (NASDAQ:PGEN) are both medical companies, but which is the superior business? We will compare the two businesses based on the strength of their dividends, media sentiment, valuation, risk, profitability, analyst recommendations, earnings and institutional ownership. Do analysts rate CNTA or PGEN? Centessa Pharmaceuticals currently has a consensus price target of $28.10, indicating a potential upside of 73.78%. Precigen has a consensus price target of $6.00, indicating a potential upside of 294.74%. Given Precigen's higher probable upside, analysts plainly believe Precigen is more favorable than Centessa Pharmaceuticals.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Centessa Pharmaceuticals 0 Sell rating(s) 0 Hold rating(s) 11 Buy rating(s) 0 Strong Buy rating(s) 3.00Precigen 0 Sell rating(s) 0 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 3.00 Does the media prefer CNTA or PGEN? In the previous week, Centessa Pharmaceuticals had 7 more articles in the media than Precigen. MarketBeat recorded 8 mentions for Centessa Pharmaceuticals and 1 mentions for Precigen. Precigen's average media sentiment score of 1.13 beat Centessa Pharmaceuticals' score of 0.48 indicating that Precigen is being referred to more favorably in the news media. Company Overall Sentiment Centessa Pharmaceuticals Neutral Precigen Positive Do institutionals and insiders have more ownership in CNTA or PGEN? 82.0% of Centessa Pharmaceuticals shares are owned by institutional investors. Comparatively, 33.5% of Precigen shares are owned by institutional investors. 7.1% of Centessa Pharmaceuticals shares are owned by insiders. Comparatively, 47.1% of Precigen shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth. Which has more risk & volatility, CNTA or PGEN? Centessa Pharmaceuticals has a beta of 1.45, suggesting that its stock price is 45% more volatile than the S&P 500. Comparatively, Precigen has a beta of 1.78, suggesting that its stock price is 78% more volatile than the S&P 500. Is CNTA or PGEN more profitable? Centessa Pharmaceuticals has a net margin of 0.00% compared to Precigen's net margin of -3,728.87%. Centessa Pharmaceuticals' return on equity of -40.22% beat Precigen's return on equity.Company Net Margins Return on Equity Return on Assets Centessa PharmaceuticalsN/A -40.22% -29.95% Precigen -3,728.87%-279.20%-79.74% Which has preferable earnings and valuation, CNTA or PGEN? Precigen has lower revenue, but higher earnings than Centessa Pharmaceuticals. Centessa Pharmaceuticals is trading at a lower price-to-earnings ratio than Precigen, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioCentessa Pharmaceuticals$6.85M315.26-$235.76M-$1.81-8.93Precigen$3.92M114.46-$126.24M-$0.56-2.71 SummaryCentessa Pharmaceuticals beats Precigen on 8 of the 15 factors compared between the two stocks. Get Precigen News Delivered to You Automatically Sign up to receive the latest news and ratings for PGEN and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding PGEN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart PGEN vs. The Competition Export to ExcelMetricPrecigenMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$540.18M$2.93B$5.48B$9.45BDividend YieldN/A2.49%4.01%4.03%P/E Ratio-2.7120.5328.3219.90Price / Sales114.46266.81409.9885.24Price / CashN/A41.6635.9658.29Price / Book11.697.808.325.67Net Income-$126.24M-$55.10M$3.24B$258.18M7 Day Performance-17.39%4.62%3.08%2.81%1 Month Performance2.70%17.99%10.92%13.53%1 Year Performance-7.88%2.21%34.24%17.68% Precigen Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)PGENPrecigen4.0689 of 5 stars$1.52-16.9%$6.00+294.7%-5.3%$540.18M$3.92M-2.71190Positive NewsGap DownHigh Trading VolumeCNTACentessa Pharmaceuticals3.3433 of 5 stars$16.06+2.4%$28.10+75.0%+72.0%$2.14B$6.85M-8.87200Analyst ForecastInsider TradeBEAMBeam Therapeutics2.0652 of 5 stars$21.03+1.3%$48.75+131.8%-20.4%$2.11B$63.52M-4.56510Analyst UpgradeAnalyst RevisionTWSTTwist Bioscience4.4321 of 5 stars$34.77-1.1%$50.40+45.0%-36.3%$2.08B$312.97M-10.70990Positive NewsKNSAKiniksa Pharmaceuticals International3.4323 of 5 stars$28.42-2.1%$39.33+38.4%+29.2%$2.07B$423.24M-113.68220Positive NewsAnalyst ForecastIRONDisc Medicine3.3763 of 5 stars$59.38+2.8%$95.73+61.2%+32.2%$2.06BN/A-15.1530Analyst ForecastGLPGGalapagos0.3004 of 5 stars$32.14+3.2%$25.33-21.2%+20.4%$2.05B$288.19M0.001,310CGONCG Oncology2.5111 of 5 stars$26.90+0.6%$55.30+105.6%-25.3%$2.05B$1.14M-17.8161Gap DownARWRArrowhead Pharmaceuticals3.9051 of 5 stars$14.71-12.2%$43.71+197.2%-48.0%$2.03B$3.55M-10.51400High Trading VolumeHRMYHarmony Biosciences4.8351 of 5 stars$35.25+0.1%$51.00+44.7%+9.7%$2.02B$714.73M13.45200News CoveragePositive NewsAnalyst ForecastAnalyst RevisionDNLIDenali Therapeutics4.5963 of 5 stars$13.83-1.2%$33.71+143.8%-41.1%$2.01B$330.53M-5.18430Upcoming Earnings Related Companies and Tools Related Companies CNTA Competitors BEAM Competitors TWST Competitors KNSA Competitors IRON Competitors GLPG Competitors CGON Competitors ARWR Competitors HRMY Competitors DNLI Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:PGEN) was last updated on 7/23/2025 by MarketBeat.com Staff From Our PartnersINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredGoogle did what!?!?A new technology has sparked a modern-day gold rush in Silicon Valley. OpenAI’s Sam Altman invested $375M. Bil...Stansberry Research | SponsoredTrump’s betrayal exposed Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredAltucher: Turn $900 into $108,000 in just 12 months?Bitcoin is breaking out — and one state just created a Strategic Crypto Reserve. James Altucher says this m...Paradigm Press | SponsoredTurn $1K into $50K with This DeFi GemI've never been more confident about a DeFi opportunity. This isn't about complex trading or risky bets. Th...Crypto 101 Media | SponsoredSpecial gold investment soars 2,300% ... 5,090% ... 9,850%In my 54 years as an investor, I’ve seen my share of gold bull markets. But nothing comes close to the rall...Weiss Ratings | SponsoredHedge fund legend humiliates Bitcoin tradersLarry Benedict made $274 million trading on Wall Street… Barron’s ranked his hedge fund in the top 1% world...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Precigen, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Precigen With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free PGEN Stock Alerts